ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BNT162 Vaccine

Also written as “BNT162b2”, “BNT162b1” and “BNT162b2 Vaccine”.

Its studies are mostly in COVID-19 · Influenza, Human · Pneumococcal Infections, led by 3 companies.

Drug pageBNT162 Vaccine: every studyAll 58 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 14, 202023 company-led studies, 3 open or runningNext primary completion: Apr 21, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTechits history only202 open or runningphase 4since Oct 14, 2020Apr 27, 2020Apr 21, 2027phase 3 · NCT07798648
Pfizer20 open or runningphase 3since May 10, 2021May 10, 2021none ahead
PharmaJetits history only11 open or runningphase 2since Apr 3, 2025Apr 3, 2025none ahead

Also a collaborator on its studies: Fosun Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2021First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT04887948 · 570 enrolled · United States
  2. Jan 30, 2024Phase 2 study in Influenza, HumanNCT06237049 · 644 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06237049Influenza, Human · United States2CompletedSep 13, 2024644
NCT04887948Pneumococcal Infections · United States3CompletedDec 8, 2021570

How it is read

Names in the registry

  • “BNT162b2”, 16 entries
  • “BNT162b1”, 3 entries
  • “BNT162b2 Vaccine”, 2 entries
  • “BNT162b2 (Omi XBB.1.5)”, 2 entries
  • “BNT162b2 (2025/2026 formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.